Diabetes/Metabolism Research and Reviews Journal Impact Factor & Information

Publisher: Wiley

Journal description

Diabetes/Metabolism Research and Reviews is a print and electronic journal that publishes original research articles and reviews in diabetes and related areas of metabolism. The journal is dedicated to publishing papers with the shortest achievable lead times. The Editor-in-Chief and Co-Editors will consider original articles on the aetiology and pathogenesis of diabetes as well as treatment and management issues related to patient care. Areas of controversy are especially welcome. The reviews section serves the community of clinicians and researchers by providing an ongoing update of clinical and basic scientific advances in the most important areas of diabetes and metabolism.

Current impact factor: 3.59

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 3.593
2012 Impact Factor 2.968
2011 Impact Factor 3.373
2010 Impact Factor 3.094
2009 Impact Factor 2.762
2008 Impact Factor 3.149

Impact factor over time

Impact factor

Additional details

5-year impact 3.16
Cited half-life 6.10
Immediacy index 1.01
Eigenfactor 0.01
Article influence 0.98
Website Diabetes/Metabolism Research and Reviews website
Other titles Diabetes/metabolism research and reviews (Online), Diabetes/metabolism research and reviews, Diabetes metabolism research and reviews
ISSN 1520-7560
OCLC 39529047
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details


  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Some journals have separate policies, please check with each journal directly
    • On author's personal website, institutional repositories, arXiv, AgEcon, PhilPapers, PubMed Central, RePEc or Social Science Research Network
    • Author's pre-print may not be updated with Publisher's Version/PDF
    • Author's pre-print must acknowledge acceptance for publication
    • On a non-profit server
    • Publisher's version/PDF cannot be used
    • Publisher source must be acknowledged with citation
    • Must link to publisher version with set statement (see policy)
    • If OnlineOpen is available, BBSRC, EPSRC, MRC, NERC and STFC authors, may self-archive after 12 months
    • If OnlineOpen is available, AHRC and ESRC authors, may self-archive after 24 months
    • Publisher last contacted on 07/08/2014
    • This policy is an exception to the default policies of 'Wiley'
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: To examine the dose-response association between cumulative genetic risk and actual risk of type 2 diabetes mellitus (T2DM) and the influence of adjustment for covariates on T2DM risk through a comprehensive meta-analysis of observational studies. Electronic literature search using EMBASE and MEDLINE (from 2003 to 2014) was conducted for cross-sectional or longitudinal studies that presented the odds ratio (OR) for T2DM in each group with categories based on the total number of risk alleles (RAs) carried (RAtotal ) using at least 2 single nucleotide polymorphisms. Spline regression model was used to determine the shape of the relationship between the difference from the referent group of each study in RAtotal (ΔRAtotal ) and natural logarithms of ORs (log OR) for T2DM. Sixty-five eligible studies that included 68,267 cases among 182,603 participants were analyzed. In both crude and adjusted ORs, defined by adjusting the risk for at least 2 confounders among age, gender, and BMI, the slope of the log OR for T2DM became less steep as the ΔRAtotal increased. In the analysis limited to 14 cross-sectional and 4 longitudinal studies presenting both crude and adjusted ORs, regression curves of both ORs in relation to ΔRAtotal were almost identical. Using only SNPs for T2DM screening was of limited value. However, when genotypic T2DM risk was considered independently from risk in relation to covariates, it was suggested that genetic profiles might have a supplementary role related to conventional T2DM risk factors in identifying individuals at high risk of T2DM. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 08/2015; DOI:10.1002/dmrr.2680
  • Diabetes/Metabolism Research and Reviews 07/2015; Accepted.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes is a major public health problem and thought to be a risk factor for infectious diseases, but pertinent epidemiological evidence is limited. This study aimed to analyse the associations of diabetes, disease duration, and glycated hemoglobin levels (HbA1c) with infectious diseases mortality in the general population, including the investigation of potential non-linear relationships. An observational, prospective study of 19,783 subjects included in the Third National Health and Nutrition Examination Survey, representing the adult non-institutionalized population of the United States of America, was conducted. The analysis was done by multiple Cox regression and restricted cubic spline modelling. Self-reported diabetes and diabetes duration were not significantly associated with the outcomes. However, there was evidence for a non-linear association of HbA1c with mortality from influenza, pneumonia, or other acute lower respiratory infections. Spline regression suggested a roughly doubled risk of mortality beyond a HbA1c of 6.5% (48 mmol/mol) in reference to 5.2% (33 mmol/mol). Future studies on diabetes and infections should adequately address potential non-linearity, which may be necessary to better understand and characterise more precisely the relationship of diabetes with infectious diseases. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 07/2015; DOI:10.1002/dmrr.2681
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although the association of Helicobacter pylori (H. pylori) infection with diabetes mellitus has been evaluated, findings are controversial. This study investigated the association in a Chinese population. A cross-sectional study, including a total of 30,810 subjects from the Dongfeng-Tongji Cohort study was conducted. H. pylori status was measured via (14) C urea breath test. Association analysis was performed by logistic regression, with multivariable adjustment for sex, age, BMI, smoking, alcohol consumption, family history of diabetes, physical activity, and the use of antibiotics. Among a middle- and old-age Chinese population, Individuals with H. pylori infection also had a higher prevalence of type 2 diabetes (21.3% vs.20.2%, P = 0.026). H. pylori infection was associated with higher risk of type 2 diabetes (OR, 1.08 [95% CI: 1.02-1.14]; P = 0.008) after adjustment for other confounders. The association was significant among females, those who were above 65 years old, not overweight or obese, and those who did not smoke, did not consume alcohol and without family history of diabetes. However, there was no interaction between H. pylori infection and other traditional risk factors on type 2 diabetes risk. Subjects with H. pylori infection had a lower level of HDL cholesterol (P < 0.0001) and higher levels of blood pressure (P < 0.001), total cholesterol, HbA1c and fasting blood glucose (P < 0.0001) than those who did not. These findings suggested that H. pylori infection was associated with the risk of type 2 diabetes in a middle- and old-age Chinese population. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 07/2015; DOI:10.1002/dmrr.2677
  • [Show abstract] [Hide abstract]
    ABSTRACT: Type 2 diabetes is linked with cognitive dysfunction and dementia in epidemiological studies, but these observations are limited by lack of data on the exact timing of diabetes onset. We investigated diabetes, dysglycaemia, and cognition in the Finnish Diabetes Prevention Study (DPS), in which the timing and duration of diabetes is well documented. The DPS comprised middle-aged, overweight participants with impaired glucose tolerance (IGT) but no diabetes at baseline (n = 522), randomized to lifestyle intervention or a control group. After an intervention period (mean duration 4 years) and follow-up (additional 9 years), cognitive assessment with the CERAD test battery and Trail Making Test A (TMT) was executed twice within a two-year interval. Of the 364 (70%) participants with cognitive assessments, 171 (47%) had developed diabetes. Cognitive function did not differ between those who developed diabetes and those who did not. Lower mean 2-h glucose at an oral glucose tolerance test (OGTT) and HbA1C during the intervention period predicted better performance in the TMT (p = 0.012 and 0.024, respectively). Those without diabetes or with short duration of diabetes improved in CERAD total score between the two assessments (p = 0.001) whereas those with long duration of diabetes did not (p = 0.844). Better glycemic control among persons with baseline IGT predicted better cognitive performance 9 years later in this secondary analysis of the DPS study population. In addition, learning effects in cognitive testing were not evident in people with long diabetes duration. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 07/2015; DOI:10.1002/dmrr.2679
  • Diabetes/Metabolism Research and Reviews 07/2015; 31(5):479-480. DOI:10.1002/dmrr.2639
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cellular muscular aponeurotic fibrosarcoma(c-maf) is a member of the large macrophage-activating factor family. C-Maf plays important roles in the morphogenetic processes and cellular differentiation of the lens, kidneys, liver, T cells, and nervous system, and it is particularly important in pancreatic islets and erythroblastic island formation. However, the exactly role of c-Maf remains to be elucidated. In this review, we summarize the research to clarify the functions of c-maf in the cellular development and differentiation. The expression of c-Maf is higher in pancreatic duct cells than in pancreatic islet cells. Therefore, we suggest that pancreatic duct cells may be converted to the functional insulin secreting cells by regulating c-Maf. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2676
  • [Show abstract] [Hide abstract]
    ABSTRACT: The metabolic syndrome (MetS) predicts cardiovascular risk and incident type 2 diabetes mellitus (T2DM). The presence of a MetS is defined by the clustering of ≥3 out of 5 cardiometabolic criteria (hyperglycemia; hypertension; enlarged waist; low HDL-cholesterol; and hypertriglyceridemia), each of which is connected with insulin resistance (IR). It is not known whether the severity of MetS, ranked from the sextet of scores' range [0/5 to 5/5], is linearly related to reduced insulin sensitivity (IS) and/or lesser hyperbolic product across the glycemic spectrum. 839 adults (54 normoglycemic; 785 with abnormal glucose homeostasis, among whom 711 T2DM) had IS assessed together with their cardiometabolic phenotype. There was a significant gradient according to interval-scale MetS score in insulinemia; BMI; (visceral) fat; hepatic steatosis; and macroangiopathy. There was an inverse linear relationship between increasing MetS scores and decreased IS, allowing to define an IR-predicting linear equation: IS (%) = [-15.1*MetS score] + 109.4 (R(2) = 0.221). For each MetS category, mean IS values did not significantly differ between groups of patients across the glycemic spectrum. The hyperbolic product (β-cell function x IS) and/or its loss rate were inversely related to MetS severity. IS is linearly and inversely related to MetS severity across the 6 scores. This novel way to exploit information intrinsic to the MetS criteria provides an easy and costless means to quantify IS across the glycemic spectrum. Moreover, MetS severity is associated with a lesser hyperbolic product, and a higher loss of the latter. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2675
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increasing evidence suggests that a history of type 2 diabetes mellitus (type 2 DM) may be involved in the development of various sites of cancer. However, the association with risk of gallbladder cancer (GBC) remains unclear. We identified studies by a literature search of MEDLINE and EMBASE through August 31, 2014, and by searching the reference lists of pertinent articles. All data were independently extracted by two investigators using a standardized data abstraction tool. Summary relative risks (SRRs) with 95% confidence intervals (CIs) were calculated with a random-effects model. A total of 20 studies (8 case-control studies and 12 cohort studies) were included in this meta-analysis. Analysis of these 20 studies found that compared with non-diabetic individuals, diabetic individuals had an increased risk of GBC (SRR = 1.56, 95% CI: 1.36-1.79). There was evidence of moderate heterogeneity among these studies (P = 0.010 and I(2) = 43.5%). This increased risk relationship is independent of smoking, body mass index and a history of gallstones. However, whether or not controlled for alcohol use may be one of the potential confounders, which significantly affect the association between type 2 DM and the risk of GBC. Diabetic women and men had a similarly increased risk of GBC associated with type 2 DM. These findings of this systematic review indicate that compared with non-diabetic individuals, individuals with type 2 DM had an increased risk of GBC development in both men and women. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2671
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this work was to investigate the potential mediating effect of oxidative stress, inflammation and coagulation on Mediterranean diet- diabetes link. In 2001-02, a random sample of 1514 men (18-87 years old) and 1528 women (18-89 years old) was selected to participate in the ATTICA study, where Athens is a major metropolis. A validated questionnaire was used to assess lifestyle and dietary factors. Adherence to Mediterranean diet was recorded using MedDietScore. Among others, oxidative stress and inflammatory biomarkers were recorded. During 2011-2012, the 10-year follow-up was performed. Diabetes incidence was defined according to American Diabetes Association criteria. 191 incident cases of diabetes were documented, yielding to an incidence of 12.9% (13.4% in men and 12.4% in women). Medium and high adherence were found to decrease diabetes risk by 49% (95%CI: 0.30, 0.88), and 62% (95%CI: 0.16, 0.88) respectively, compared to low adherence. A logarithmic trend between Mediterranean diet and diabetes incidence was also revealed (p for trend = 0.042). Individuals with abnormal waist circumference (>94 for men, >80 for women) were benefited the most. Wholegrain cereals, fruits and legumes had the greatest predictive ability. The anti-diabetic effect of Mediterranean diet was mediated by TNF-α, homocysteine and TAC. The reported results underline the role of Mediterranean diet as a promising dietary tool for the primary prevention of diabetes, by attenuating inflammation and fostering TAC; thus, this dietary pattern may have a therapeutic potential for a plethora of cardio-metabolic disorders, resulting from inflammation and/or oxidative stress. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2672
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to investigate the role of common variants in the genes SLC30A8, KCNQ1, and TCF7L2 in the association between birth weight and increased risk of type 2 diabetes in Han Chinese. Seven variants (SLC30A8- rs13266634 and rs2466293; KCNQ1- rs2237895 and rs2074196; and TCF7L2- rs11196218, rs7903146, and rs290487) were genotyped in 1,181 individuals born in Peking Union Medical College Hospital from 1921 to 1954 by Taqman allelic discrimination assay. All the subjects were stratified by birth weight into groups of ≥3000 g and <3000 g. Associations of genetic variants with birth weight and with risk of type 2 diabetes and impaired glucose tolerance (together as impaired glucose metabolism, IGM) were analyzed. After adjustment for sex, gestational weeks, parity, and maternal age, the G allele of KCNQ1-rs2074196 was associated with higher birth weight (p = 0.032). KCNQ1-rs2074196, rs2234895, and TCF7L2-rs290487 were associated with increased risk of IGM. However, the associations were modified by size at birth. The associations above were only found in subjects with birth weights greater than (or equal to) 3000 g. In subjects with birth weights less than 3000 g, IGM was associated with variants SLC30A8-rs2466293 and TCF7L2-rs11196218. The role of common variants in susceptible genes in the development of IGM was modified by birth weight in Han Chinese. This provides evidence that genetic variants influence birth weight and are involved in development of type 2 diabetes. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2670
  • [Show abstract] [Hide abstract]
    ABSTRACT: The proposed 2015 United States Preventive Services Task Force guidelines recommend diabetes screening for individuals ≥45 years or demonstrating other risk factors for dysglycemia. Still, many patients with dysglycemia remain undiagnosed and opportunities for early intervention are lost. To test novel approaches for diagnosis using a Hemoglobin A1c (HbA1c ) test, we screened adult patients who were admitted to an observation unit from the emergency department with no known history of pre-diabetes or diabetes. Of 256 subjects, 9% were newly diagnosed with diabetes and 52% were newly diagnosed with pre-diabetes. Of those aged 18-29 years, 33% were newly diagnosed with dysglycemia, while 55% of those aged 30-44 years and 70% of those aged ≥45 years were newly diagnosed with dysglycemia. Our results suggest that regardless of age, large proportions of patients in the emergency department observation unit have undiagnosed dysglycemia, an important finding given the large number of observation admissions. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2674
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Growing evidence suggests the presence of a complex interplay between hypertension as well as type 2 diabetes mellitus (DM) and osteoporosis. The present study was designed to investigate a possible impact of type 2 DM on bone remodeling markers such as osteoprotegerin (OPG) and N-terminal propeptide of type 1 collagen (P1NP) in hypertensive patients.Design and Methods The 100 study participants were divided into three groups according to presence of DM and hypertension: group one included diabetic hypertensive subjects, group 2 included hypertensive subjects without diabetes and group 3 included subjects without hypertension and DM (controls). Blood sampling for metabolic parameters, including OPG, P1NP, adiponectin, fasting glucose, HbA1C, CRP, HOMA-IR, HOMA-beta function was performed.ResultsCirculating P1NP increased from Group 1 to Group 3 in a continuous fashion. P1NP was significantly lower in hypertensive subjects with DM (Group 1), than in Group 2 and 3 (p < 0.0001). P1NP, was marginally lower in diabetic hypertensive subjects as compared to nondiabetics with hypertension (p = 0.079). Circulating OPG did not differ significantly between groups (p = 0.593).Conclusions In the present study, bone formation marker, PINP, was significantly lower in diabetic hypertensive subjects as compared to nondiabetics with and without hypertension. P1NP was inversely associated with parameters of glucose homeostasis such as fasting glucose, HBA1C and positively with HOMA-beta cell function. Type 2 DM was associated with an adverse effect on bone formation independently of age, sex and exposure to antidiabetic drugs. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 06/2015; DOI:10.1002/dmrr.2668
  • [Show abstract] [Hide abstract]
    ABSTRACT: Type 2 diabetes is a complex and multifaceted disease requiring an individualized approach. A special attention, in treating the patients, should be devoted to the presence of comorbidities like overweight or obesity and arterial hypertension. Among the available anti-hyperglycemic agents, several are associated with side effects like hypoglycaemia and weight gain. An increasing interest is reported in SGLT2 inhibitors, a relatively novel class of glucose-lowering drugs that act independently of insulin, provide benefits beyond glucose-lowering actions, and show a better tolerability compared with traditional medications for type 2 diabetes. This review tries to offer a balanced view on the main extra-glycemic effects of empagliflozin, also mentioning clinical data obtained with other SGLT2 inhibitors; the role of the proximal tubule in the pathophysiology of diabetic nephropathy and the potential nehroprotection exerted by this compound are also briefly discussed. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 05/2015; DOI:10.1002/dmrr.2666
  • [Show abstract] [Hide abstract]
    ABSTRACT: Metabolic syndrome (MetS) appears closely linked with ceramide accumulation inducing insulin resistance and toxicity to multiple cell types. Animal studies demonstrate that thiazolidinediones (TZDs) reduce ceramide concentrations in plasma and skeletal muscle and support lowering of ceramide levels as a potential mediator of TZDs' mechanism of action in reducing insulin resistance; however, studies in humans have yet to be reported. This study investigated the effects of pioglitazone therapy on plasma ceramides to understand the mechanism by which TZDs improve insulin resistance in MetS. 37 subjects with MetS were studied in a single-center, randomized, double-blind, placebo-controlled, trial comparing pioglitazone to placebo. Data were collected at baseline and after 6 months of therapy. The primary endpoint was the change from baseline in plasma ceramide concentrations. Treatment with pioglitazone for 6 months, compared to placebo, significantly reduced multiple plasma ceramide concentrations: C18:0 (p = .001), C20:0 (p = .0004), C24:1 (p = .009), dihydroceramide C18:0 (p = .005), dihydroceramide C24:1 (p = .004), lactosylceramide C16:0 (p = .02) and the hexosylceramides C16:0 (p = .0003), C18:0 (p = 0.00001), C22:0 (p = .00002) and C24:1 (p = .0006). Additionally, significant reductions were found when ceramides were grouped by species: ceramides (p = .03), dihydroceramides (p = .02), hexosylceramides (p = .00001), and lactosylceramides (p = .02). The total of all measured ceramides was also significantly reduced (p = .001). Following treatment with pioglitazone, the decrease in some ceramide species correlated negatively with the change in insulin sensitivity (dihydroceramide C16:0, r = -.54; p = .02), and positively with total (lactosylceramide C24:0, r = .53; p = .02) and high molecular weight (lactosylceramide C24:0, r = .48; p = .05) adiponectin measurements; however, significant associations with changes in liver fat and glycemic control reduction were not found. Pioglitazone in individuals with MetS induces a potent decrease in plasma ceramides, and some of the changes correlate with changes in insulin resistance and adiponectin levels. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 05/2015; DOI:10.1002/dmrr.2662